Business Wire

SOLAR-PROMOTION-GMBH

7.5.2024 17:54:32 CEST | Business Wire | Press release

Share
Fields and the Sun: Agricultural PV, an Opportunity for the Energy and the Farming Industry

The EU’s objectives are ambitious: The total solar energy deployment is to reach around 750 gigawatts by 2030. In this context, dual land use concepts, especially agricultural PV, are gaining importance. At Intersolar Europe, the world’s leading exhibition for the solar industry, visitors will have the opportunity to see a varied range of technologies, products and solutions for agricultural PV, and to gain deeper insights into best practices and the latest developments. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, in Munich.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507054567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Latest tracking systems for agricultural PV applications will be presented at the "Intersolar Europe Special Exhibit Agrivoltaics". (© BayWa r.e.)

Agriculture or renewable sources of energy – in the past, it was either, or. Agricultural PV is a new, innovative approach offering promising options for agriculture and climate protection by joining agricultural production and the generation of electricity on the same surface.

Extensive subsidies

European countries such as Germany and France subsidize agricultural PV with the aim of deploying more solar energy while reducing the competition for land use. Germany has introduced a separate auction segment with a top value for “special solar installation” (which includes agricultural PV installations) in the Solar Package 1, and France is deemed one of the pioneers for dedicated legislation. Other countries, such as Austria and the Netherlands, also promote their agricultural PV sector.

Benefits of agricultural PV

The advantages of dual land use are obvious: It reconciles solar energy with agriculture, and the protection against storm, hale, frost and draught adds an extra bonus for farmers. The electricity production costs are lower than from small roof-mounted installations, and farmers’ income is diversified. Shading and wind protection provided by solar panels reduces evaporation, and innovative solar panels have been developed that also collect rainwater for irrigation. This can benefit farming operations by boosting their resilience against crop failure.

Best practice projects

Pilot projects are emerging all over Europe. In the Dutch local authority of Meierijstad, for example, BayWa r.e. AG and their subsidiary GroenLeven are implementing a pioneering agricultural PV project, a 8.7 megawatt peak solar installation covering a vast raspberry plantation. On Sicily, figs and olives grow between the module rows of Europe’s largest agricultural PV plant. In Neißeaue, Germany, Next2Sun Technology works on a 20 megawatts solar farm with vertical modules.

Intersolar Europe 2024: special attention on agricultural PV

Intersolar Europe is putting a particular focus on agricultural PV. A special exhibit in the Outdoor Area will be dedicated to the topic. Partners of the special exhibit are BayWa AG, BayWa r.e., Conexio PSE, Vista Geo and ZIMMERMANN PV-Steel Group. What’s more, of the more than 1,370 Intersolar Europe exhibitors, some 60 exhibitors will be showcasing agricultural PV products and solutions. Experts will dive deeper into the topic and offer even wider information at a number of sessions at the Intersolar Forum and the Intersolar Europe Conference.

Intersolar Europe

As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.

Further information: www.intersolar.de/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507054567/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye